EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need

Przemysław Zygmunciak, Tadeusz Robak iD, Bartosz Puła iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25031589 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Przemysław Zygmunciak und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent years have seen significant improvement in chronic lymphocytic leukemia (CLL) management. Targeting B-cell lymphoma (BCL-2) and Bruton’s kinase (BTK) have become the main strategies to restrain CLL activity. These agents are generally well tolerated, but the discontinuation of these therapies happens due to resistance, adverse effects, and Richter’s transformation. A growing population of patients who have previously used both BTK inhibitors and BCL2 suffer from the constriction of the following regimens. This review explores the resistance mechanisms for both ibrutinib and venetoclax. Moreover, we present innovative approaches evaluated for treating double-refractory CLL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, B-CellHumansProtein-Tyrosine KinasesAgammaglobulinaemia Tyrosine KinaseProtein Kinase Inhibitors

Stichwörter der Autor:innen

BCL-2 inhibitorsBTK degradersBTK inhibitorsCAR-TPI3K inhibitorschronic lymphocytic leukemia

Substanzen

Protein-Tyrosine KinasesAgammaglobulinaemia Tyrosine KinaseProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Institute of Hematology and Transfusion Medicine, 02-776 Warsaw, Poland.
  • Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
  • Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland.

ORCID-Profile: Tadeusz Robak, Bartosz Puła

Zitieren

APA

Zygmunciak, P., Robak, T., & Puła, B. (2024). Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25031589

Vancouver

Zygmunciak P, Robak T, Puła B. Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25031589

BibTeX
@article{Zygmunciak2024,
  author = {Zygmunciak, Przemysław and Robak, Tadeusz and Puła, Bartosz},
  title = {Treatment of Double-Refractory Chronic Lymphocytic Leukemia—An Unmet Clinical Need},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25031589}
}
Kostenlos starten →